BIOA BioAge Labs, Inc.
Price Chart
Executive Summary
BioAge Labs reported its full-year 2025 financial results alongside key clinical and corporate updates, including positive Phase 1 data for its NLRP3 inhibitor BGE-102, expansion into ophthalmology, and completion of a $132.3 million follow-on offering. The company now has $285.1 million in cash, funding operations through 2029. While collaboration revenue rose to $9.0 million, R&D and G&A expenses increased, resulting in a net loss of $80.6 million.
Key Financial Metrics
Actionable Insight
The positive biomarker data for BGE-102 supports its potential as a best-in-class oral NLRP3 inhibitor, with upcoming Phase 2a readouts in 2026 serving as key catalysts. The expanded indication into DME diversifies clinical risk. While fundamentals remain pre-revenue and loss-making, the strong cash position de-risks near-term execution. Traders should monitor Phase 2a initiation and data timelines as potential upside triggers.
Key Facts
- Positive interim Phase 1 data for BGE-102 showed 86% median reduction in hsCRP, 58% in IL-6, and 30% in fibrinogen in obese patients with elevated inflammation.
- Phase 2a proof-of-concept trial in cardiovascular risk to initiate in 1H 2026; data expected in 2H 2026.
- BGE-102 program expanded into diabetic macular edema (DME), with Phase 1b/2a trial planned for mid-2026.
- Completed upsized follow-on offering raising $132.3 million in gross proceeds, strengthening cash position.
- Cash, cash equivalents, and marketable securities totaled $285.1 million as of December 31, 2025, sufficient to fund operations through 2029.
- Collaboration revenue was $9.0 million in 2025 (vs. $0 in 2024), driven by the Novartis partnership.
- R&D expenses rose to $73.9 million (from $59.0 million in 2024), primarily due to BGE-102 and APJ agonist programs, partially offset by termination of azelaprag.
- Net loss was $80.6 million in 2025 ($2.24 per share), compared to $71.1 million ($6.63 per share) in 2024.
Financial Impact
Revenue increased by $9.0 million due to Novartis collaboration, but R&D and G&A expenses rose by $14.9M and $8.6M respectively, leading to a larger net loss. However, the $132.3M capital raise significantly extends runway.
Risk Factors
- Clinical development risk: BGE-102 is still in early stages; Phase 2a data may not confirm efficacy.
- Dilution from the follow-on offering: 6.8M shares issued, increasing share count by ~18%.
- High cash burn: Despite extended runway, R&D spending is accelerating, and future financings may be needed before commercialization.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3261303 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 8, 2026
15d ago
|
8-K
| $17.99 $18.72 | ▲ +4.03% | ▲ +2.57% | $16.61 (−7.67%) |
|
Apr 21, 2026
4w ago
|
DEFA14A
| $18.36 $17.14 | ▼ −6.64% | ▼ −6.70% | $16.61 (−9.53%) |
|
Apr 21, 2026
4w ago
|
Press Release
| $19.61 $17.44 | ▼ −11.07% | ▼ −12.15% | $16.61 (−15.30%) |
|
Apr 1, 2026
7w ago
|
144
| $17.73 $17.79 | ▲ +0.34% | ▼ −3.43% | $16.61 (−6.32%) |
|
Mar 24, 2026
8w ago
|
Press Release
| $16.11 $17.49 | ▲ +8.57% | ▲ +8.99% | $16.61 (+3.10%) |
|
Feb 28, 2026
12w ago
|
Institutional Cluster
| $21.71 $19.73 | ▼ −9.12% | ▼ −7.91% | $16.61 (−23.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access